Medicare Enrolled

Dr. James Alderman, MD

Cardiovascular Disease · Framingham, MA
Low-engagement
99 LINCOLN ST, Framingham, MA 01702
5088754811
In practice since 2005 (20 years)
NPI: 1457342065 verify on NPPES ↗
High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Alderman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Alderman? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Alderman

Dr. James Alderman is a cardiovascular disease specialist in Framingham, MA, with 20 years of NPI registration.

Between the years covered by Open Payments, Dr. Alderman received a total of $3,888 from 29 pharmaceutical and/or device companies across 186 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Alderman is High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice $3,888 industry payments

Industry Payment Transparency

Open Payments through 2022 ↗
$3,888
Total received (2018-2022)
Avg $778/year across 5 years
Top 35% in MA for cardiovascular disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
29
Companies
186
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,867 (99.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$21 (0.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2022
$950
2021
$650
2020
$142
2019
$660
2018
$1,485

Payments by company (2022)

Consulting
Speaking
Meals & Travel
Research
Janssen Pharmaceuticals, Inc
$269
E.R. Squibb & Sons, L.L.C.
$151
AstraZeneca Pharmaceuticals LP
$108
Novartis Pharmaceuticals Corporation
$66
Amgen Inc.
$57
Alnylam Pharmaceuticals Inc.
$55
Actelion Pharmaceuticals US, Inc.
$54
Novo Nordisk Inc
$47
Kiniksa Pharmaceuticals, Ltd.
$39
Esperion Therapeutics, Inc.
$35
Merck Sharp & Dohme LLC
$35
Bayer HealthCare Pharmaceuticals Inc.
$18
Medtronic, Inc.
$16
Top 3 companies account for 55.6% of 2022 payments
All-time payments by company (2018-2022) ›
Janssen Pharmaceuticals, Inc
$714
Novartis Pharmaceuticals Corporation
$467
E.R. Squibb & Sons, L.L.C.
$335
Amgen Inc.
$319
AstraZeneca Pharmaceuticals LP
$284
Boehringer Ingelheim Pharmaceuticals, Inc.
$209
Regeneron Healthcare Solutions, Inc.
$186
PFIZER INC.
$158
Gilead Sciences, Inc.
$147
Esperion Therapeutics, Inc.
$125
Alnylam Pharmaceuticals Inc.
$109
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$106
SANOFI-AVENTIS U.S. LLC
$85
Edwards Lifesciences Corporation
$79
BIOTRONIK INC.
$75
Amarin Pharma Inc.
$72
Medtronic, Inc.
$61
Actelion Pharmaceuticals US, Inc.
$54
Novo Nordisk Inc
$47
Merck Sharp & Dohme Corporation
$40
Kiniksa Pharmaceuticals, Ltd.
$39
Merck Sharp & Dohme LLC
$35
Chiesi USA, Inc.
$26
Abbott Laboratories
$24
Terumo Medical Corporation
$23
Philips Electronics North America Corporation
$22
Bayer HealthCare Pharmaceuticals Inc.
$18
Opsens Inc.
$18
CHIESI USA, INC.
$11
Top 3 companies account for 39.0% of all-time payments
Associated products mentioned in payments ›
(8333) IGT D Coronary · ATTAIN COMMAND + SUREVALVE · Arcalyst · Asahi Fielder coronary guide wire · BRILINTA · CAMZYOS · CARDENE · CHANTIX · CLEVIPREX · CLEVIPREX 50MG/100ML · Corlanor · ELIQUIS · ENTRESTO · FARXIGA · GlideWire · JARDIANCE · Kerendia · LEQVIO · LifeVest · Micra · NEXLETOL · ONPATTRO · OptoWire · Ozempic · PRADAXA · PRALUENT · PRALUENT ALIROCUMAB INJECTION · Repatha · UPTRAVI · VERQUVO · Vascepa · XARELTO
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a cardiovascular disease specialist in Framingham?
Compare cardiologists in the Framingham area by procedure volume, costs, and industry payment transparency.
Browse cardiologists nearby

Geographic Context

Cardiologists within 10 mi
588
Per 100K population
36.2
County median income
$126,779
Nearest hospital
METROWEST MEDICAL CENTER
2.6 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data — No data N/A
Industry Payments Open Payments CY 2022
Disciplinary History — Not public N/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Alderman is a cardiovascular disease specialist, with low-engagement industry engagement, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Does Dr. Alderman receive payments from pharmaceutical companies?
Yes. Dr. Alderman received a total of $3,888 from 29 companies across 186 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently High for Dr. Alderman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →